Health-related quality of life in ovarian cancer patients and its impact on clinical management

References

• American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, Atlanta, GA, USA (2010).
   Google Scholar
• von Gruenigen VE, Huang HQ, Gil KM et al. A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J. Pain Symptom Manage.39(5), 839–846 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J. Natl Cancer Inst.96(14), 1083–1094 (2004).
   PubMedGoogle Scholar
• Madalinska JB, Hollenstein J, Bleiker E et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clin. Oncol.23(28), 6890–6898 (2005).
   PubMed Web of Science ®Google Scholar
• Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol. Oncol.112(3), 594–600 (2009).
   PubMed Web of Science ®Google Scholar
• Kauff ND, Hurley KE, Hensley ML et al. Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. Cancer104(2), 314–320 (2005).
   PubMedGoogle Scholar
• Greene MH, Piedmonte M, Alberts D et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol. Biomarkers Prev.17(3), 594–604 (2008).
   PubMedGoogle Scholar
• Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.23(24), 5605–5612 (2005).
   PubMed Web of Science ®Google Scholar
• Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol.108(1), 100–105 (2008).
   PubMed Web of Science ®Google Scholar
• Wenzel LB, Huang HQ, Armstrong DK et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol.25(4), 437–443 (2007).
   PubMed Web of Science ®Google Scholar
• Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med.363(10), 943–953 (2010).
   PubMed Web of Science ®Google Scholar
• Greimel ER, Bjelic-Radisic V, Pfisterer J et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J. Clin. Oncol.24(4), 579–586 (2006).
   PubMed Web of Science ®Google Scholar
• Greimel ER, Bjelic-Radisic V, Pfisterer J et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support. Care Cancer DOI: 10.1007/s00520-010-0969-8 (2010) (Epub ahead of print).
   Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol.28(20), 3323–3329 (2010).
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a Phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol.26(19), 3176–3182 (2008).
   PubMed Web of Science ®Google Scholar
• Rustin G, van der Burg M, Griffin C, Qian W, Swart AM. Early versus delayed treatment of relapsed ovarian cancer. Lancet377(9763), 380–381 (2011).
   PubMedGoogle Scholar
• Greimel E, Daghofer F, Petru E. Prospective assessment of quality of life in long-term ovarian cancer survivors. Int. J. Cancer128(12), 3005–3011 (2011).
   PubMedGoogle Scholar
• Gotay CC, Kawamoto CT, Bottomley A et al. The prognostic significance of patient reported outcomes in cancer clinical trials. J. Clin. Oncol.26, 1355–1363 (2008).
   PubMed Web of Science ®Google Scholar
• Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist12(Suppl. 1), 11–21 (2007).
   PubMed Web of Science ®Google Scholar
• Kearney N, Miller M, Maguire R et al. WISECARE+: results of a European study of a nursing intervention for the management of chemotherapy-related symptoms. Eur. J. Oncol. Nurs.12(5), 443–448 (2008).
   PubMedGoogle Scholar
• Butt Z, Rosenbloom SK, Abernethy AP et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J. Natl Compr. Canc. Netw.6(5), 448–455 (2008).
   PubMedGoogle Scholar
• Holzner B, Kemmler G, Meraner V et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer97(6), 1564–1572 (2003).
   PubMed Web of Science ®Google Scholar
• Mirabeau-Beale KL, Kornblith AB, Penson RT et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol. Oncol.114(2), 353–359 (2009).
   PubMed Web of Science ®Google Scholar
• Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann. Oncol.20(1), 17–25 (2009).
   PubMed Web of Science ®Google Scholar
• Luckett T, King MT. Choosing patient-reported outcome measures for cancer clinical research – practical principles and an algorithm to assist non-specialist researchers. Eur. J. Cancer46(18), 3149–3157 (2010).
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Kornblith A, Lee H et al. Long-term adjustment of early-stage ovarian cancer survivors. Int. J. Gynecol. Cancer18(6), 1183–1193 (2008).
   PubMed Web of Science ®Google Scholar
• Traeger L, Braun IM, Greer JA, Temel JS, Cashavelly B, Pirl WF. Parsing depression from fatigue in patients with cancer using the fatigue symptom inventory. J. Pain Symptom Manage.42(1), 52–59 (2011).
   PubMed Web of Science ®Google Scholar
• Weinrib AZ, Sephton SE, Degeest K et al Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer116(18), 4410–4419 (2010).
   PubMed Web of Science ®Google Scholar
• Banasik J, Williams H, Haberman M, Blank SE, Bendel R. Effect of Iyengar yoga practice on fatigue and diurnal salivary cortisol concentration in breast cancer survivors. J. Am. Acad. Nurse Pract.23(3), 135–142 (2011).
   PubMed Web of Science ®Google Scholar
• Dean-Clower E, Doherty-Gilman AM, Keshaviah A et al. Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr. Cancer Ther.9(2), 158–167 (2010).
   PubMed Web of Science ®Google Scholar
• Stevinson C, Steed H, Faught W et al. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int. J. Gynecol. Cancer19(1), 73–78 (2009).
   PubMed Web of Science ®Google Scholar
• Danhauer SC, Tooze JA, Farmer DF et al. Restorative yoga for women with ovarian or breast cancer: findings from a pilot study. J. Soc. Integr. Oncol.6(2), 47–58 (2008).
   PubMedGoogle Scholar
• Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist12(Suppl. 1), 52–67 (2007).
   PubMed Web of Science ®Google Scholar
• Gibson F, Aldiss S, Taylor RM, Maguire R, Kearney N. Involving health professionals in the development of an advanced symptom management system for young people: the ASyMS-YG study. Eur. J. Oncol. Nurs.13(3), 187–192 (2009).
   PubMed Web of Science ®Google Scholar
• McCann L, Maguire R, Miller M, Kearney N. Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur. J. Cancer Care18(2), 156–164 (2009).
   PubMed Web of Science ®Google Scholar
• Wenzel L, Huang HQ, Cella D, Walker JL, Armstrong DK, Gynecologic Oncology Group. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol. Oncol.110(1), 60–64 (2008).
   PubMedGoogle Scholar
• Husain A, Bezjak A, Easson A. Malignant ascites symptom cluster in patients referred for paracentesis. Ann. Surg. Oncol.17(2), 461–469 (2010).
   PubMedGoogle Scholar
• Easson AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann. Surg. Oncol.14(8), 2348–2357 (2007).
   PubMedGoogle Scholar
• Keen A, Fitzgerald D, Bryant A, Dickinson HO. Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst. Rev.20(1), CD007794 (2010).
   Google Scholar
• Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol. Oncol.111(3), 530–532 (2008).
   PubMed Web of Science ®Google Scholar
• von Gruenigen VE, Huang HQ, Gil KM et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer115(20), 4857–4864 (2009).
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Broadwater G, Davis DM et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol. Oncol.113(2), 216–220 (2009).
   PubMed Web of Science ®Google Scholar
• Bezjak A, Tu D, Bacon M et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J. Clin. Oncol.22(22), 4595–4603 (2004).
   PubMed Web of Science ®Google Scholar
• Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. ‘What doesn’t kill you makes you stronger’: an ovarian cancer survivor survey. Gynecol. Oncol.83(3), 537–542 (2001).
   PubMed Web of Science ®Google Scholar
• Fitch MI, Gray RE, Franssen E. Women’s perspectives regarding the impact of ovarian cancer: implications for nursing. Cancer Nurs.23(5), 359–366 (2000).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Kornblith AB, Wong G et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer74(3), 907–915 (1994).
   PubMed Web of Science ®Google Scholar
• Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am. J. Ther.17(2), 148–158 (2010).
   PubMedGoogle Scholar
• Pignata S, De Placido S, Biamonte R et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer6, 5 (2006).
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Bogliun G, Marzorati L et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann. Oncol.15(9), 1439–1442 (2004).
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Welshman EE, Chang CH et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int. J. Gynecol. Cancer13, 741–748 (2003).
   PubMed Web of Science ®Google Scholar
• Albers J, Chaudhry V, Cavaletti G et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev.CD005228 (2007).
   Google Scholar
• Hilpert F, Stähle A, Tomé O et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy – a double-blind, placebo-controlled, randomized Phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support. Care Cancer13(10), 797–805 (2005).
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support. Care Cancer14(11), 1134–1140 (2006).
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A et al. vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology64(1), 26–31 (2005).
   PubMed Web of Science ®Google Scholar
• Kim HK, Zhang YP, Gwak YS, Abdi S. Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology112(2), 432–439 (2010).
   PubMedGoogle Scholar
• Garg MB, Ackland SP. Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. Cancer Chemother. Pharmacol.67(4), 963–966 (2011).
   PubMedGoogle Scholar
• Reis N, Beji NK, Coskun A. Quality of life and sexual functioning in gynecological cancer patients: results from quantitative and qualitative data. Eur. J. Oncol. Nurs.14(2), 137–146 (2010).
   PubMed Web of Science ®Google Scholar
• Carter J, Chi DS, Brown CL et al. Cancer-related infertility in survivorship. Int. J. Gynecol. Cancer20(1), 2–8 (2010).
   PubMed Web of Science ®Google Scholar
• Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J. Clin. Oncol.26(5), 753–758 (2008).
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Miller AM, Champion VL et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J. Clin. Oncol.25(19), 2792–2797 (2007).
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Spriggs D, Aghajanian C et al. Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol. Oncol.116(1), 66–71 (2010).
   PubMedGoogle Scholar
• du Bois A, Herrstedt J, Hardy-Bessard AC et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J. Clin. Oncol.28(27), 4162–4169 (2010).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Weber B, Reuss A et al. Randomized Phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl Cancer Inst.98(15), 1036–1045 (2006).
   PubMed Web of Science ®Google Scholar
• du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin–paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J. Clin. Oncol.24(7), 1127–1135 (2006).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst.96(22), 1682–1691 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol.26(6), 890–896 (2008).
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol.25(19), 2811–2818 (2007).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol.24(29), 4699–4707 (2006).
   PubMed Web of Science ®Google Scholar